Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.950
-0.010 (-0.51%)
At close: Apr 28, 2026, 4:00 PM EDT
1.940
-0.010 (-0.51%)
After-hours: Apr 28, 2026, 7:55 PM EDT
Palisade Bio Employees
Palisade Bio had 14 employees as of December 31, 2025. The number of employees increased by 6 or 75.00% compared to the previous year.
Employees
14
Change (1Y)
6
Growth (1Y)
75.00%
Revenue / Employee
n/a
Profits / Employee
-$1,198,643
Market Cap
326.48M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14 | 6 | 75.00% |
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Cabaletta Bio | 156 |
| Nautilus Biotechnology | 130 |
| Silence Therapeutics | 88 |
| Compass Therapeutics | 39 |
| DiaMedica Therapeutics | 35 |
| Ovid Therapeutics | 23 |
| Monopar Therapeutics | 22 |
PALI News
- 12 days ago - Palisade Bio Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 12 days ago - Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 - GlobeNewsWire
- 20 days ago - Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Palisade Bio Transcript: Study result - Transcripts
- 4 weeks ago - Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease - GlobeNewsWire
- 2 months ago - Palisade Bio Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Palisade Bio Announces Participation in Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Palisade Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts